熱門資訊> 正文
Innate Pharma报告900万个结果
2025-11-13 19:32
- Innate Pharma press release (IPHA): 9M Revenues amounted to €2.3 million (€10.2 million for the same period in 2024). For the nine-month period, ended September 30, 2025, revenue from collaboration and licensing agreements mainly resulted from the partial or entire recognition of the proceeds received pursuant to the agreements with AstraZeneca and Sanofi.
More on Innate Pharma
- Innate Pharma S.A. (IPHA) Analyst/Investor Day Transcript
- Innate Pharma S.A. (IPHA) Analyst/Investor Day - Slideshow
- Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Innate Pharma
- Historical earnings data for Innate Pharma
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
